AVDL
Price
$19.23
Change
+$0.08 (+0.42%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
1.88B
115 days until earnings call
Intraday BUY SELL Signals
DERM
Price
$7.69
Change
-$1.39 (-15.31%)
Updated
Nov 13 closing price
Capitalization
208.95M
125 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AVDL vs DERM

Header iconAVDL vs DERM Comparison
Open Charts AVDL vs DERMBanner chart's image
Avadel Pharmaceuticals
Price$19.23
Change+$0.08 (+0.42%)
Volume$25.18K
Capitalization1.88B
Journey Medical
Price$7.69
Change-$1.39 (-15.31%)
Volume$864.5K
Capitalization208.95M
AVDL vs DERM Comparison Chart in %
View a ticker or compare two or three
VS
AVDL vs. DERM commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVDL is a Buy and DERM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (AVDL: $19.15 vs. DERM: $9.08)
Brand notoriety: AVDL and DERM are both notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AVDL: 81% vs. DERM: 216%
Market capitalization -- AVDL: $1.88B vs. DERM: $208.95M
AVDL [@Pharmaceuticals: Generic] is valued at $1.88B. DERM’s [@Pharmaceuticals: Generic] market capitalization is $208.95M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVDL’s FA Score shows that 0 FA rating(s) are green whileDERM’s FA Score has 0 green FA rating(s).

  • AVDL’s FA Score: 0 green, 5 red.
  • DERM’s FA Score: 0 green, 5 red.
According to our system of comparison, AVDL is a better buy in the long-term than DERM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVDL’s TA Score shows that 5 TA indicator(s) are bullish while DERM’s TA Score has 6 bullish TA indicator(s).

  • AVDL’s TA Score: 5 bullish, 5 bearish.
  • DERM’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, DERM is a better buy in the short-term than AVDL.

Price Growth

AVDL (@Pharmaceuticals: Generic) experienced а +1.00% price change this week, while DERM (@Pharmaceuticals: Generic) price change was +2.71% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.08%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +32.16%.

Reported Earning Dates

AVDL is expected to report earnings on Mar 09, 2026.

DERM is expected to report earnings on Mar 19, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AVDL($1.88B) has a higher market cap than DERM($209M). DERM YTD gains are higher at: 132.225 vs. AVDL (82.207). AVDL has higher annual earnings (EBITDA): 7.87M vs. DERM (-1.19M). AVDL has more cash in the bank: 81.5M vs. DERM (20.3M). AVDL has less debt than DERM: AVDL (2.73M) vs DERM (25.3M). AVDL has higher revenues than DERM: AVDL (221M) vs DERM (56.4M).
AVDLDERMAVDL / DERM
Capitalization1.88B209M899%
EBITDA7.87M-1.19M-662%
Gain YTD82.207132.22562%
P/E RatioN/A39.08-
Revenue221M56.4M392%
Total Cash81.5M20.3M401%
Total Debt2.73M25.3M11%
FUNDAMENTALS RATINGS
AVDL vs DERM: Fundamental Ratings
AVDL
DERM
OUTLOOK RATING
1..100
3483
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
4288
SMR RATING
1..100
9297
PRICE GROWTH RATING
1..100
3739
P/E GROWTH RATING
1..100
3836
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DERM's Valuation (74) in the Biotechnology industry is in the same range as AVDL (82) in the Medical Specialties industry. This means that DERM’s stock grew similarly to AVDL’s over the last 12 months.

AVDL's Profit vs Risk Rating (42) in the Medical Specialties industry is somewhat better than the same rating for DERM (88) in the Biotechnology industry. This means that AVDL’s stock grew somewhat faster than DERM’s over the last 12 months.

AVDL's SMR Rating (92) in the Medical Specialties industry is in the same range as DERM (97) in the Biotechnology industry. This means that AVDL’s stock grew similarly to DERM’s over the last 12 months.

AVDL's Price Growth Rating (37) in the Medical Specialties industry is in the same range as DERM (39) in the Biotechnology industry. This means that AVDL’s stock grew similarly to DERM’s over the last 12 months.

DERM's P/E Growth Rating (36) in the Biotechnology industry is in the same range as AVDL (38) in the Medical Specialties industry. This means that DERM’s stock grew similarly to AVDL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVDLDERM
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
87%
Declines
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AVDL
Daily Signal:
Gain/Loss:
DERM
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
APRAF0.200.01
+2.86%
Trailbreaker Resources Ltd.
DSNKY22.500.39
+1.76%
Daiichi Sankyo Co., Ltd.
MDRSF100.00N/A
N/A
MEDARTIS HOLDING AG
TETHF0.88N/A
N/A
Tethys Petroleum, Ltd.
SKLTY34.19N/A
N/A
Seek Ltd

AVDL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVDL has been loosely correlated with RMTI. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if AVDL jumps, then RMTI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVDL
1D Price
Change %
AVDL100%
+1.70%
RMTI - AVDL
35%
Loosely correlated
-9.04%
ELAN - AVDL
32%
Poorly correlated
-3.54%
BCRX - AVDL
29%
Poorly correlated
-0.69%
VTRS - AVDL
28%
Poorly correlated
-1.70%
EBS - AVDL
27%
Poorly correlated
-0.64%
More

DERM and

Correlation & Price change

A.I.dvisor tells us that DERM and ETON have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DERM and ETON's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DERM
1D Price
Change %
DERM100%
+0.33%
ETON - DERM
29%
Poorly correlated
-1.13%
AQST - DERM
27%
Poorly correlated
-1.93%
CHRS - DERM
27%
Poorly correlated
+0.74%
AVDL - DERM
23%
Poorly correlated
+1.70%
PRGO - DERM
22%
Poorly correlated
-0.98%
More